Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL27830007

CC(C)(C)OC(=O)N1CCN(CCN)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
TLR8 Q9NR97 1/20 0.40
ACKR3 P25106 3/20 0.39
DPP4 P27487 1/20 0.39
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
GPR119 Q8TDV5 1/20 0.37
EPHX2 P34913 1/20 0.37
ALOX15 P16050 1/20 0.37
ABCB1 P08183 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL27848401 0.92 TLR8 (0.43) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL12644325 0.91 USP2 (0.50) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL46682 0.91 USP2 (0.50) USP2SMN1; SMN2CHRM2CHRM4CHRM1
Ammonia Solution, Strong SCHEMBL208691 0.90 USP2 (0.49) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL7687 0.82 TLR8 (0.48) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL6221438 0.82 TLR8 (0.48) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL311100 0.82 CHRM2 (0.50) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL30772318 0.81 CYP2D6 (0.44) USP2SMN1; SMN2HPGDGPR119EPHX2
SCHEMBL8242595 0.81 USP2 (0.61) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL943825 0.81 TLR8 (0.47) USP2SMN1; SMN2CHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101910158-A Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders ASTRAZENECA AB 2010-12-08 CN disclosed